Teva Pharmaceuticals announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a US New Drug Application (NDA) submission is anticipated in the second half of 2026.

Richard Francis, President and Chief Executive Officer (CEO), Teva Pharmaceuticals, said, “This acquisition reflects our Pivot to Growth strategy in action, advancing our innovative pipeline through focused, capital-efficient business development. It adds a late-stage opportunity with potential to address a significant unmet need in Tourette syndrome, and with our deep neuroscience expertise, we are well-positioned to advance this program.” 

Emalex Biosciences was created by Paragon Biosciences to develop new treatments for Central Nervous System (CNS) disorders. Emalex, supported by Paragon, advanced the asset through clinical development and compiled the NDA submission for pediatric Tourette syndrome.